MoonLake Immunotherapeutics (MLTX) Short Interest Ratio & Short Volume $42.36 +0.92 (+2.22%) As of 12:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MoonLake Immunotherapeutics Short Interest DataMoonLake Immunotherapeutics (MLTX) has a short interest of 6.63 million shares, representing 12.52% of the float (the number of shares available for trading by the public). This marks a 4.41% increase in short interest from the previous month. The short interest ratio (days to cover) is 16.1, indicating that it would take 16.1 days of the average trading volume of 447,381 shares to cover all short positions.Current Short Interest6,630,000 sharesPrevious Short Interest6,350,000 sharesChange Vs. Previous Month+4.41%Dollar Volume Sold Short$243.79 millionShort Interest Ratio16.1 Days to CoverLast Record DateApril 15, 2025Outstanding Shares64,012,000 sharesFloat Size52,940,000 sharesShort Percent of Float12.52%Today's Trading Volume113,301 sharesAverage Trading Volume447,381 sharesToday's Volume Vs. Average25% Short Selling MoonLake Immunotherapeutics? Sign up to receive the latest short interest report for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMLTX Short Interest Over TimeMLTX Days to Cover Over TimeMLTX Percentage of Float Shorted Over Time MoonLake Immunotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20256,630,000 shares $243.79 million +4.4%12.5%16.1 $36.77 3/31/20256,350,000 shares $248.09 million -12.3%12.0%13.8 $39.07 3/15/20257,240,000 shares $279.10 million -2.7%13.7%18.2 $38.55 2/28/20257,440,000 shares $310.69 million -7.6%14.1%21.4 $41.76 2/15/20258,050,000 shares $347.84 million +4.8%15.3%24.2 $43.21 1/31/20257,680,000 shares $353.20 million -1.5%14.6%24.2 $45.99 1/15/20257,800,000 shares $342.97 million -3.5%14.8%26 $43.97 12/31/20248,080,000 shares $437.53 million +0.5%15.3%32.2 $54.15 12/15/20248,040,000 shares $412.77 million +0.5%15.2%29 $51.34 11/30/20248,000,000 shares $435.44 million No Change15.2%26.6 $54.43 Get the Latest News and Ratings for MLTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/20248,000,000 shares $390.64 million -0.7%15.2%26.1 $48.83 10/31/20248,060,000 shares $374.15 million -1.1%15.3%26.7 $46.42 10/15/20248,150,000 shares $391.20 million +2.3%15.5%25.4 $48.00 9/30/20247,970,000 shares $401.85 million +2.6%15.2%22.3 $50.42 9/15/20247,770,000 shares $397.36 million -2.1%14.8%23.8 $51.14 8/31/20247,940,000 shares $371.51 million +2.3%15.1%25.2 $46.79 8/15/20247,760,000 shares $372.79 million -0.1%14.8%22.7 $48.04 7/31/20247,770,000 shares $323.62 million -1.8%14.8%21.5 $41.65 7/15/20247,910,000 shares $386.80 million +1.0%15.1%22.6 $48.90 6/30/20247,830,000 shares $344.29 million +0.1%14.9%23.3 $43.97 6/15/20247,820,000 shares $323.83 million -0.8%14.9%22.1 $41.41 5/31/20247,880,000 shares $320.40 million +8.2%15.0%20.2 $40.66 5/15/20247,280,000 shares $296.22 million +5.1%14.0%16.3 $40.69 4/30/20246,930,000 shares $283.51 million -4.6%14.0%15 $40.91 4/15/20247,260,000 shares $316.83 million -5.1%15.4%15.4 $43.64 3/31/20247,650,000 shares $384.26 million +9.3%16.2%15.9 $50.23 3/15/20247,000,000 shares $330.75 million +0.9%14.8%14.8 $47.25 2/29/20246,940,000 shares $334.79 million +5.0%14.7%14.5 $48.24 2/15/20246,610,000 shares $396.80 million -0.9%14.1%13.3 $60.03 1/31/20246,670,000 shares $372.72 million -3.2%14.5%12.2 $55.88 1/15/20246,890,000 shares $401.69 million -0.3%15.0%10.4 $58.30 12/31/20236,910,000 shares $417.29 million -8.0%15.0%9.6 $60.39 12/15/20237,510,000 shares $455.48 million -4.1%16.3%10.4 $60.65 11/30/20237,830,000 shares $343.82 million +7.0%17.7%10.9 $43.91 11/15/20237,320,000 shares $287.38 million +10.2%16.6%10.6 $39.26 10/31/20236,640,000 shares $344.02 million -6.4%16.7%10.4 $51.81 10/15/20237,090,000 shares $387.61 million +3.5%19.7%13.8 $54.67 9/30/20236,850,000 shares $390.45 million +4.1%19.0%14.1 $57.00 9/15/20236,580,000 shares $369.93 million -1.2%15.6%8.7 $56.22 8/31/20236,660,000 shares $383.42 million -10.1%16.8%9.1 $57.57Donald Trump is about to free crypto from its chains … (Ad)Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.There's another coin he thinks could do even better. 8/15/20237,410,000 shares $417.03 million +10.6%18.7%10.1 $56.28 7/31/20236,700,000 shares $407.43 million +1.8%16.8%9.2 $60.81 7/15/20236,580,000 shares $357.10 million +6.8%15.2%8.9 $54.27 6/30/20236,160,000 shares $314.16 million +33.9%17.2%8.8 $51.00 6/15/20234,600,000 shares $125.12 million +12.5%13.9%8.5 $27.20 5/31/20234,090,000 shares $111.29 million -5.3%12.8%10.5 $27.21 5/15/20234,320,000 shares $115.60 million +30.1%13.6%12.2 $26.76 4/30/20233,320,000 shares $70.72 million +78.5%12.0%11 $21.30 4/15/20231,860,000 shares $35.41 million +0.5%6.7%6.9 $19.04 3/31/20231,850,000 shares $39.57 million +119.4%6.5%9.1 $21.39 3/15/2023843,300 shares $17.13 million -4.5%2.7%4.7 $20.31 2/28/2023883,400 shares $16.95 million +44.4%2.8%6.9 $19.19 2/15/2023611,800 shares $10.27 million -0.1%1.9%6 $16.79 1/31/2023612,600 shares $7.32 million -0.8%1.9%7.6 $11.95 1/15/2023617,300 shares $7.34 million +0.7%1.9%8.8 $11.89 12/30/2022612,800 shares $6.43 million -14.7%1.9%10.1 $10.50 12/15/2022718,100 shares $6.75 million -15.1%2.3%12.5 $9.40 11/30/2022845,400 shares $8.39 million +38.1%2.7%18.9 $9.93 11/15/2022612,200 shares $5.48 million +0.8%2.0%14.5 $8.95 10/31/2022607,100 shares $5.00 million +1.0%2.0%13.3 $8.24 10/15/2022601,400 shares $5.29 million +0.7%2.0%11 $8.80 9/30/2022597,000 shares $4.63 million +2.5%2.0%10.3 $7.76 9/15/2022582,300 shares $4.48 million +1.5%2.0%11.7 $7.69 8/31/2022573,900 shares $4.63 million -3.4%1.9%9.7 $8.06 8/15/2022594,100 shares $4.24 million -7.2%1.8%6.8 $7.13 7/31/2022640,100 shares $4.03 million +6.5%1.9%7.7 $6.30 7/15/2022601,300 shares $3.53 million No Change1.8%6.6 $5.87 MLTX Short Interest - Frequently Asked Questions What is MoonLake Immunotherapeutics' current short interest? Short interest is the volume of MoonLake Immunotherapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 6,630,000 shares of MLTX short. 12.52% of MoonLake Immunotherapeutics' shares are currently sold short. Learn More on MoonLake Immunotherapeutics' current short interest. What is a good short interest ratio for MoonLake Immunotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MLTX shares currently have a short interest ratio of 16.0. Learn More on MoonLake Immunotherapeutics's short interest ratio. Which institutional investors are shorting MoonLake Immunotherapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of MoonLake Immunotherapeutics: Group One Trading LLC, Citadel Advisors LLC, Jane Street Group LLC, Parallax Volatility Advisers L.P., and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for MoonLake Immunotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.52% of MoonLake Immunotherapeutics' floating shares are currently sold short. Is MoonLake Immunotherapeutics' short interest increasing or decreasing? MoonLake Immunotherapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 6,630,000 shares, an increase of 4.4% from the previous total of 6,350,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is MoonLake Immunotherapeutics' float size? MoonLake Immunotherapeutics currently has issued a total of 64,012,000 shares. Some of MoonLake Immunotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. MoonLake Immunotherapeutics currently has a public float of 52,940,000 shares. How does MoonLake Immunotherapeutics' short interest compare to its competitors? 12.52% of MoonLake Immunotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to MoonLake Immunotherapeutics: Viatris Inc. (3.96%), Qiagen (2.11%), Roivant Sciences Ltd. (11.68%), Revolution Medicines, Inc. (10.62%), Lantheus Holdings, Inc. (10.23%), BridgeBio Pharma, Inc. (15.57%), TG Therapeutics, Inc. (16.90%), Legend Biotech Co. (5.49%), Sarepta Therapeutics, Inc. (7.51%), ADMA Biologics, Inc. (5.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short MoonLake Immunotherapeutics stock? Short selling MLTX is an investing strategy that aims to generate trading profit from MoonLake Immunotherapeutics as its price is falling. MLTX shares are trading down $0.64 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against MoonLake Immunotherapeutics? A short squeeze for MoonLake Immunotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MLTX, which in turn drives the price of the stock up even further. How often is MoonLake Immunotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MLTX, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Viatris Short Interest Data Qiagen Short Interest Data Roivant Sciences Short Interest Data Revolution Medicines Short Interest Data Lantheus Short Interest Data BridgeBio Pharma Short Interest Data TG Therapeutics Short Interest Data Legend Biotech Short Interest Data Sarepta Therapeutics Short Interest Data ADMA Biologics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MLTX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.